37830-21-0 Usage
Derivative of phenylacetate
Modified from the basic structure of phenylacetate a compound with potential applications in pharmaceuticals and organic synthesis.
Contains a cyclopentyl group
A five-carbon cyclic alkyl group (C5H9) attached to the phenylacetate structure, which may influence its chemical properties and potential applications.
Contains a hydroxy group
A functional group (-OH) present in the molecule, which can form hydrogen bonds and participate in various chemical reactions, affecting its properties and potential uses.
Contains a 1-methylpiperidin-4-yl substituent
A nitrogen-containing heterocyclic group (C6H10N) with a methyl group (CH3) attached to the 1st carbon and the piperidine ring at the 4th position, which can influence the compound's chemical reactivity and pharmaceutical activity.
Potential pharmaceutical applications
May be used as a medication for mental health disorders or as a precursor in organic synthesis, though further research is needed to fully understand its properties and potential uses.
Check Digit Verification of cas no
The CAS Registry Mumber 37830-21-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,7,8,3 and 0 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 37830-21:
(7*3)+(6*7)+(5*8)+(4*3)+(3*0)+(2*2)+(1*1)=120
120 % 10 = 0
So 37830-21-0 is a valid CAS Registry Number.
37830-21-0Relevant articles and documents
Carry over of impurities: A detailed exemplification for glycopyrrolate (NVA237)
Allmendinger, Thomas,Bixel, Dominique,Clarke, Adrian,Di Geronimo, Laura,Fredy, Jean-Wilfried,Manz, Marco,Gavioli, Elena,Wicky, Regine,Schneider, Martin,Stauffert, Fabien J.,Tibi, Markus,Valentekovic, Darko
, p. 1754 - 1769 (2013/01/15)
The original synthesis of glycopyrrolate (NVA237) was revised and shortened into an essentially one-pot process. Without isolating the intermediates, their purification became obsolete, thereby increasing the possibility of the carry over of impurities. For that reason, the actual, potential, and theoretical impurities of the starting materials cyclopentyl mandelic acid and 1-methyl-pyrrolidin-3-ol as well as byproducts which may occur during the synthesis were thoroughly investigated; furthermore, their transformation to possible impurities in the drug substance along the new synthetic route was performed to exclude them as actual impurities in the drug substance with certainty. The question is raised how detailed such investigation-which are fairly manageable for a simple product like glycopyrrolate-need to be.
